Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maksim Mamonkin

Blood

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Blood|June 10, 2015
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignanciesMaksim Mamonkin, Rayne H Rouce, Haruko Tashiro, et al.
Blood|May 26, 2017
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignanciesDiogo Gomes-Silva, Madhuwanti Srinivasan, Sandhya Sharma, et al.
Blood|August 31, 2022
Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantationFeiyan Mo, Norihiro Watanabe, Kayleigh I Omdahl, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood|August 1, 2022
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignanciesAbdullah Freiwan, Jaquelyn T Zoine, Jeremy Chase Crawford, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Blood|June 10, 2015
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignanciesMaksim Mamonkin, Rayne H Rouce, Haruko Tashiro, et al.
Blood|May 26, 2017
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignanciesDiogo Gomes-Silva, Madhuwanti Srinivasan, Sandhya Sharma, et al.
Blood|August 31, 2022
Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantationFeiyan Mo, Norihiro Watanabe, Kayleigh I Omdahl, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood|August 1, 2022
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignanciesAbdullah Freiwan, Jaquelyn T Zoine, Jeremy Chase Crawford, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Pageof 1